Cost-effectiveness of drug-eluting stents in a US medicare setting: A cost-utility analysis with 3-year clinical follow-up data

Value in Health

Volumn 12, Issue 5, 2009, Pages 649-656

  Bischof, Matthias ^a,b   Briel, Matthias ^a,c   Bucher, Heiner C ^a   Nordmann, Alain ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Cardiology; Cost utility analysis; Decision analytic model; Drug eluting stents

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG ELUTING STENT; HEALTH CARE COST; HUMAN; MEDICARE; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; STATISTICAL MODEL; SYSTEMATIC REVIEW; UNITED STATES;

CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG-ELUTING STENTS; HUMANS; MARKOV CHAINS; MEDICARE; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RISK; STENTS; UNITED STATES;

EID: 67649908716     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00513.x     Document Type: Article

References (43)

1. Mensah G, Brown D. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood) 2007 26 : 38 48.
2. Al Suwaidi J, Berger P, Holmes D. Coronary artery stents. JAMA 2000 284 : 1828 36.
3. Serruys P, Unger F, Sousa J, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001 344 : 1117 24.
4. Maisel W. Unanswered questions - drug-eluting stents and the risk of late thrombosis. N Engl J Med 2007 356 : 981 4.
5. Ligthart S, Vlemmix F, Dendukuri N, Brophy J. The cost-effectiveness of drug-eluting stents: a systematic review. CMAJ 2007 176 : 199 205. (Pubitemid 46168380)
6. Stone G, Moses J, Ellis S, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007 356 : 998 1008. (Pubitemid 46376800)
7. Babapulle M, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004 364 : 583 91.
8. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007 356 : 989 97.
9. Hill R, Bagust A, Bakhai A, et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004 8 : iii 242.
10. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007 356 : 1030 9.
11. Nordmann A, Briel M, Bucher H. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006 27 : 2784 814.
12. Katritsis D, Karvouni E, Ioannidis J. Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol 2005 95 : 640 3.
13. Brophy J, Erickson L. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. Int J Technol Assess Health Care 2005 21 : 326 33.
14. Bagust A, Grayson A, Palmer N, et al. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. Heart 2006 92 : 68 74. (Pubitemid 43021858)
15. Kaiser C, Brunner-La Rocca H, Buser P, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005 366 : 921 9.
16. Lord S, Howard K, Allen F, et al. A systematic review and economic analysis of drug-eluting coronary stents available in Australia. Med J Aust 2005 183 : 464 71.
17. Shrive F, Manns B, Galbraith P, et al. Economic evaluation of sirolimus-eluting stents. CMAJ 2005 172 : 345 51.
18. Hout B, Serruys P, Lemos P, et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart 2005 91 : 507 12.
19. Ryan J, Cohen D. Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation 2006 114 : 1736 43.
20. Eisenberg M. Drug-eluting stents: the price is not right. Circulation 2006 114 : 1745 54.
21. Ruffy R, Kaden RJ. Projected health and economic benefits of the use of sirolimus-eluting coronoary stents. Adv Stud Med 2003 3 (6D 602 11.
22. Greenberg D, Bakhai A, Cohen D. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol 2004 43 : 513 18.
23. Greenberg D, Cohen D. Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent. Z Kardiol 2002 91 (Suppl. 3137 143.
24. Cohen D, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004 110 : 508 14.
25. Bakhai A, Stone G, Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV trial. J Am Coll Cardiol 2006 48 : 253 61.
26. Sculpher M, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ 2006 15 : 677 87.
27. Sonnenberg F, Beck J. Markov models in medical decision making: a practical guide. Med Decis Making 1993 13 : 322 38.
28. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis, 2nd edn. London, UK : Chapman & Hall/CRC, 2003.
29. Hankey G, Jamrozik K, Broadhurst R, et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 2000 31 : 2080 6.
30. Furman M, Dauerman H, Goldberg R, et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 2001 37 : 1571 80.
31. Witt B, Brown R, Jacobsen S, et al. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med 2005 143 : 785 92.
32. Serruys P, Ong A, van Herwerden L, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005 46 : 575 81.
33. Hellermann J, Jacobsen S, Redfield M, et al. Heart failure after myocardial infarction: clinical presentation and survival. Eur J Heart Fail 2005 7 : 119 25.
34. Hannan E, Racz M, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005 352 : 2174 83.
35. Centers for Medicare & Medicaid Services [Internet Available from: http://www.cms.hhs.gov/ [Accessed February 15, 2008 EM, Mehta S, Yuan Y, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J 2006 151 : 219 27.
36. Best Hospitals 2007 specialty search: heart [Internet Available from: http://health.usnews.com/usnews/health/best-hospitals/search.php?spec= ihqcard& [Accessed April 22, 2008 EA, Walters SJ. Continuing inequality: gender and social class influences on self perceived health after a heart attack. J Epidemiol Community Health 2003 57 : 622 7.
37. Hill RA, Boland A, Dickson R, et al. Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess 2007 11 : iii, xi 221.
38. Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998 18 (2 Suppl. S68 80.
39. Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005 14 : 339 47.
40. Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000 17 : 479 500. (Pubitemid 30398806)
41. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007 369 : 667 78.
42. FDA. Update to FDA Statement on Coronary Drug-Eluting Stents. Available from: http://www.fda.gov/cdrh/news/010407.html [Accessed February 15, 2008 HP, Kaiser C, Bernheim A, et al. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis. Lancet 2007 370 : 1552 9.
43. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999 18 : 341 64.